PAC 3 MSE

Bambusa Therapeutics Launches $150 Million IPO

Boston-based clinical-stage biotechnology company Bambusa Therapeutics has launched its proposed $150 million initial public offering. According to its S-1/A filing,…

PATRIOT MISSILE SHORTAGE: FOUR-YEAR DELAY LOOMS FOR DEFENSE GIANT ORDERS

WASHINGTON — Pentagon planners and foreign military attachés face a sobering industrial bottleneck: a severe Patriot missile shortage has caused…